The Preventive Era Is Here: What 2025 Gen Z Aesthetics Data Shows

Gen Z has been one of the most-discussed cohorts in medical aesthetics for the better part of a decade. Their share of the patient population has grown steadily, and their preference for preventive care has been widely noted. But now that the oldest among them are entering their late 20s, there’s a growing interest in how these patients actually move through the market once they’re in it.

Understanding a patient cohort means going beyond share figures alone. Qsight 2025 data traces Gen Z aesthetic patients across first-treatment behavior, ongoing service patterns, annual spend, and geographic demand concentration to give aesthetic medicine and beauty brands a clearer operational picture of who these patients actually are.

Key Takeaways: Gen Z & Aesthetics Industry Trends

• Gen Z enters the aesthetic market needle-first: neurotoxins are the dominant first treatment at the category level.
• Laser hair removal leads Gen Z’s ongoing aesthetic procedure activity by visit count, but Botox captures the most dollars.
• Gen Z aesthetic spending is right-skewed: a smaller high-frequency patient segment drives a disproportionate share of revenue.
• Neurotoxin share among Gen Z grew from 12% of total non-surgical spend in 2021 to 20% in 2025.
• Geographic concentration data points to specific U.S. markets where Gen Z activity is highest, giving sales teams more precise starting points for territory planning.

Gen Z Beauty Trends: How They Enter the Market

For older patient cohorts, the aesthetic journey often began with a specific concern, like a line, a spot, or a texture issue. From there, they worked toward a treatment. Gen Z is moving differently.

Among Gen Z patients entering aesthetic practices for the first time in 2025, neurotoxins are the dominant entry point at the category level, outpacing energy-based devices and non-EBD skin rejuvenation.

At the individual treatment level, first-time Gen Z aesthetic procedures rank as follows:

 

The pattern points to a cohort that is arriving at medical spas or practices with a treatment plan already in mind, rather than working up to injectables after exploring lower-commitment options first.

For brands, this has real implications for how first-touch acquisition is framed. If neurotoxins are the entry point rather than the destination, the patient education, messaging, and practice-level experience surrounding a first injectable appointment carry more weight than they might for older cohorts.

Longer-Term Beauty Industry Trends: What Gen Z Keeps Coming Back For

Once these patients are in the market, their ongoing treatment behavior splits in an interesting way, depending on how you measure it. By visit frequency, laser hair removal leads as the most common ongoing service among Gen Z patients. By total dollars spent, Botox takes the top position.

A brand or sales team measuring demand purely by transaction volume would reach different conclusions than one measuring by revenue contribution. Laser hair removal generates consistent foot traffic; neurotoxins generate the spend. Both points are useful, but they’re telling different parts of the same story.

Also worth noting is that compounded semaglutide cracked the top five most frequently used services in 2025, alongside laser hair removal, Botox, Dysport, and Hydrafacial. Weight loss medications entering the Gen Z aesthetic treatment mix is something brands in adjacent categories should be paying attention to.

Qsight data, 2025

Gen Z ongoing aesthetic treatments

The same cohort tells two different stories depending on how demand is measured

Source: Guidepoint Qsight Sales Measurement, 2025. Ongoing non-surgical services among Gen Z patients.

 

What Gen Z Actually Spends on Aesthetic Services

Aggregate spending figures for a patient cohort can obscure as much as they reveal. The average annual non-surgical spend for a Gen Z aesthetic patient in 2025 is $940, but the median is $520. The gap between those numbers is the more telling figure.

It indicates a right-skewed distribution: most Gen Z patients are spending closer to $520 per year, while a smaller segment of high-frequency, high-spend patients is pulling the average upward. That smaller segment is carrying a disproportionate share of total Gen Z revenue.

Brands and sales teams should keep in mind that not all Gen Z patients represent equal opportunity. The real commercial value lies in the ability to identify and retain the high-frequency segment early—before competitors do.

Where Neurotoxin Demand Is Concentrated in the United States

Neurotoxins clearly aren’t just a Gen Z beauty trend. Their popularity continues to grow across the non-surgical aesthetics market, jumping to $6.4 billion in 2025.

Qsight data identifies the states where each generation accounts for the largest share of total neurotoxin spending, and the leaders aren’t necessarily the markets that come to mind first.

Among all neurotoxin spending in South Carolina, 10.5% comes from Gen Z patients, the highest concentration of any state. The leaders look different across generations:

Vermont leads among Millennials at 48.9%
Arkansas leads among Gen X at 43.7%
Hawaii leads among Boomers and older at 36.8%

Each generation concentrates its neurotoxin spending in different markets, and Gen Z’s doesn’t map cleanly onto the ones that came before it.

For sales teams, that kind of generational market mapping can change how territories get prioritized, where med spa and practice outreach gets concentrated, and which markets warrant closer attention.